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1. Introduction
Peripheral nerve injuries represent a common disability around 
the world.[1] Indeed, annually more than one million people 
suffer from this kind of injury, with 300 000 of these cases in 
Europe alone.[2]
Injuries in the peripheral nervous system can result from 
working accidents, motor vehicle accidents, tumor damage, 
side effects of neurosurgery and even viral infections.[1,3] For 
this reason, the development of suitable methods to properly 
regenerate these injuries is mandatory and represents a world-
wide social need.
Experiments concerning peripheral nerve regeneration have been reported 
since the end of the 19th century. The need to implement an effective sur-
gical procedure in terms of functional recovery has resulted in the appear-
ance of several approaches to solve this problem. Nerve autograft was 
the first approach studied and is still considered the gold standard. Since 
autografts require donor harvesting, other strategies involving the use of 
natural materials have also been studied. Nevertheless, the results were 
not very encouraging and attention has moved towards the use of nerve 
conduits made from polymers, whose properties can be easily tailored and 
which allow the nerve conduit to be easily processed into a variety of shapes 
and forms. Some of these materials are already approved by the US Food 
and Drug Administration (FDA), as is presented here. Furthermore, poly-
mers with conductive properties have very recently been subject to intensive 
study in this field, since it is believed that such properties have a positive 
influence in the regeneration of the new axons. This manuscript intends to 
give a global view of the mechanisms involved in peripheral nerve regenera-
tion and the main strategies used to recover motor and sensorial function of 
injured nerves.
For the last 100 years, examples of 
degeneration and regeneration of the 
nervous system have been described in 
literature.[4] However, during the first 
40 years of investigation, the regeneration 
process was not completely known. During 
that period, nerve autografts and allografts 
were the standard techniques used to treat 
the transected nerves. Unfortunately, these 
techniques present several disadvantages, 
the worst being related to high morbidity 
and the need for immunosuppression 
treatments. Since the peripheral nervous 
system has the ability to regenerate, new 
approaches using nerve guide tubes, also 
known as nerve guide conduits (NGC), 
have been studied. A NGC can be defined 
as a tube that is sutured or fixed to the two 
stumps of the injured nerve and provides 
an adequate environment for the nerve 
regeneration.
Nowadays, it is well established that 
nerve conduits are responsible for guiding 
axon migration, maintaining the nerve 
growth factors in the space between distal and proximal stumps 
and preventing the wound healing space from being invaded by 
scar tissue and cells that could compromise the nerve recovery 
process.[5]
Nerve conduits made of several kinds of materials have been 
tested throughout the years. Among such materials, natural 
and synthetic polymers have been the most used and several 
nerve conduits based on such materials are already commer-
cially available.
This review intends to provide an overview of the regenera-
tion events that occur after a nerve injury, the strategies to pro-
mote the functional recovery of the injured nerve and the role 
of the materials that are being used to produce NGC.
2. Nervous System Regeneration
The first event occurring after a peripheral nerve injury is a 
series of cellular and molecular events called Wallerian degen-
eration, and was described for the first time by August Waller 
in 1850.[5,6] During this step, the myelin sheath is degraded and 
several axon ends are sealed, resulting in the disintegration of 
neurofilaments and microtubes.[7–9] Meanwhile, the metabo-
lism of proteins is changed, resulting in the increased syn-
thesis of regenerative materials and Schwann cells. These cells 
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start forming structures with a tube shape, known as bands of 
Büngner, in order to provide guidance for axon regeneration.[10] 
Also, they produce extracellular matrix molecules and neuro-
trophic factors that have a positive influence on the sprouting 
of new axons from the terminal nodes of Ranvier.[7,11] Although 
peripheral nervous system (PNS) axons can be fully regener-
ated, the recovery of the function is very unusual and unsatis-
factory, especially for large gaps. Due to this fact, microsurgical 
techniques were introduced by Millesi in the 1960s in order to 
improve the healing of this kind of injuries.[12] The first attempts 
consisted on simply suturing the nerve stumps (neurorhaphy). 
However, excessive tension between the two stumps can be 
harmful,[13] leading to unsatisfactory results, as functional 
recovery could not be achieved. Currently, to classify PNS inju-
ries there are two different models: Seddon and Sunderland.[14,15] 
The description of each classification is presented in Table 1.
In the most severe cases, as shown in Table 1, surgery is 
needed for the reconstruction of the nerve. Many approaches 
have appeared, nerve autographing being the most popular. 
Briefly, nerve autographing consists in harvesting a nerve seg-
ment from another site of the body to gather the stumps of the 
injured nerve. However, nerve autographing presents several 
disadvantages such as tissue availability, differences in tissue 
size and structure, and donor site morbidity.[17] In order to over-
come these disadvantages, NGC has started to be used.
3. Ideal Nerve Guide Conduit Properties
In 1882, a NGC was successfully tested for the first time in a 
dog nerve gap of 30 mm, bridged by a hollow bone tube.[18] 
Since then, many attempts to produce the ideal NGC have 
been reported and some of them were used in clinical trials in 
humans. The concept behind the NGC is to create a tubular 
structure that could bridge the two sections of the previously 
injured axon, providing guidance for the new axons and protect 
them from the scarred tissue that is formed within just a few 
days.[19] The main aim of this strategy is to increase the prob-
ability of axon regeneration as well as their length and growth 
speed.
Nowadays, it is believed that a NGC should be capable of pro-
viding mechanical support for the new fibers, guide the regen-
erated axons from the proximal to distal nerve stump, avoid 
scarred tissue infiltration and behave like a channel that allows 
the diffusion of neurotropic and neurotrophic factors secreted 
by the nerve stumps.[20] Basically, these structures should pro-
vide an adequate microenvironment for nerve regeneration. 
Figure 1 represents the steps that occur when regeneration of a 
nerve includes a tube guide.
Among the advantages of these 3D structures, in comparison 
to the old method of suturing the two stumps, is the possibility 
of stressing the reduction in neuroma, scar formation and col-
lateral sprouting of the new axons.[21] Furthermore, as the neu-
rotrophic factors secreted by the stumps become trapped inside 
the conduit, an accumulation occurs resulting in a higher con-
centration of such molecules that favor nerve regeneration. 
Their ability to provide a pathway for the new fibers to achieve 
the distal stump makes them a suitable choice for the regenera-
tion of the nerve and recovery of its functionality.
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Regarding the main properties that these devices must have, 
the most important are: biocompatibility, biodegradability, per-
meability, biomechanical properties, surface properties, custom 
dimension and interaction with neurotrophic factors.[22–25]
The biocompatibility of NGCs is evaluated considering 
three aspects: blood compatibility, histocompatibility and 
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mechanical compatibility. The first one requires that blood 
should not undergo hemolysis or damage of its components 
that could result in coagulation and formation of thrombus, 
when in contact with the NGC. The second aspect demands 
that no toxic side effects should arise from the device that 
could contaminate surrounding tissue. The last one concerns 
the mechanical properties of the NGC, which should match the 
same properties of nerve tissue.[26] As referred above, a NGC 
should provide a pathway for nerve regeneration, resist tearing 
from sutures and provide a mechanically stable architecture 
for the new tissue.[27] Therefore it should remain intact during 
the first stages of regeneration. The degradation should start 
after some time, depending on the size and type of injury, in 
a very slow way with no swelling, constriction or foreign body 
response.[28] The NGC should be semi-permeable to allow the 
diffusion of nutrients, oxygen, and growth factors to the inside 
of the tube and, at the same time, it should allow the exclu-
sion of waste products to the outside of the tube.[21,29,30] Some 
researchers believe that the material used has to be permeable 
to a molecular weight of up to 50 kDa.[21] Other aspects that 
have to be considered are both the diffusion of inflammatory 
cells to the inside of the tube, which has to be avoided, and the 
diffusion of growth factors to the outside of the tube. Since the 
permeability of the material is directly related to the porosity, it 
is reported that ideally the pore size should be between 5–30 μm, 
with preferred values in the range of 10–20 μm.[31] With pores 
smaller than 5 μm, cells and new tissue are unable to cross 
and above 30 μm the material is too permeable to inflam-
matory cells, which will compromise nerve regeneration.[26]  
It is important to mention that some of the fluid inside 
the tube should diffuse to the outside, in order to avoid a pres-
sure increase inside the conduit due to fluid retention. Since 
the main function of the NGC is to provide a pathway for nerve 
regeneration, it has to present proper biomechanical properties 
for this application.[26] A NGC should be smooth and flexible 
to avoid new fiber compression, but at the same time, it also 
requires some stiffness, as the conduit has to be resistant to 
bending without the risk of collapsing with shape loss.[23,29] Nev-
ertheless, a conduit that is too stiff can easily cause distortion 
and one which is too flexible can fail to support regeneration.[28] 
Due to these facts, the fine balance between these two proper-
ties is required. The Young modulus of a NGC should also be 
similar to those of the nerves, in order to ensure the necessary 
resistance to the common in vivo physiological loads (65-155N 
for ulnar and 73–220N for median nerves).[28] These proper-
ties are mostly dependent on the chosen material, dimensions, 
thickness, diameter of the lumen and lumen fibers, as will be 
described in the following sections. The surface properties of 
the tubes need to be evaluated, since during the formation of 
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Table 1. Classification of PNS injuries by Seddon and Sunderland (adapted).[1,14–16]
Seddon classification Sunderland classification Pathology Prognosis
Neurapraxia First degree No axon loss Spontaneous recovery time between  
hours up to a few months
Axonotmesis Second degree Axon loss Spontaneous recovery can be achieved without  
surgery depending on the distance to muscle
Third degree 2nd degree + Disruption of the endoneurial tubes Spontaneous recovery is poor due to axonal  
misdirection. Surgical intervention may be required
Fourth degree 3rd degree + Disruption of the perineurium Spontaneous recovery is worse than 3rd degree.  
Surgery is more often required.
Neurotmesis Fifth degree Entire nerve disruption. Connective tissue  
components of the nerve severed.
Recovery depends on surgical intervention
Figure 1. Nerve regeneration within a hollow NGC. Reproduced with 
permission.[21] Copyright 2012, The Royal Society.
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the new tissue, this will interact with the surface of the conduit. 
A longitudinal texture has been reported as ideal to help the 
alignment of the Schwann cells.[32] As nerve gaps differ in size 
and neurons have different diameters and sizes, the length and 
lumen dimensions of a NGC should be easily adjustable to the 
specific nerve type to be recovered.
Another approach that has been used in the design of NGC 
is the incorporation of luminal fillers, either growth factors or 
accessory cells, in the tube as a means of improving the effi-
ciency of reconstruction for both small and large gaps. Table 2 
shows the most common growth factors and their functions in 
nerve regeneration.
Schwann cells also represent an attractive class of luminal 
fillers due to their key role in the nerve regeneration process. 
Nevertheless, other accessory cells like bone-marrow stromal 
cells, ectomesenchymal stem cells and fibroblasts can be used 
to enhance the nerve regeneration process.[11]
The incorporation of these cells and growth factors in 
nerve guide conduits can be performed in different ways, 
namely: (i) use of a matrix for the delivery of growth factors 
or accessory cells. This matrix will provide support and guid-
ance for regenerating axons, control the release of growth 
factors avoiding an enzymatic breakdown and growth of sup-
portive cells. However, these growth factors and/or accessory 
cells are incorporated in a hydrogel that can be too dense 
enabling cell growth; (ii) use of an affinity-based system for 
the delivery of growth factors or accessory cells; (iii) impreg-
nating the NGC wall with accessory cells or growth factors via 
crosslinking or immobilization (diffusion-based systems). By 
crosslinking the growth factors, there is no need to use hydro-
gels, but not all crosslinking preparations are biodegradable. 
Crosslinking of different types of growth factors is also pos-
sible; (iv) direct culturing of accessory cells on the NGC wall 
which results in empty lumens not compromising the growth 
of new axons. Unfortunately the absence of supportive cells 
at the surface of the lumen can be a disadvantage; (v) using 
microspheres to delivery growth factors or accessory cells to 
the NGC lumen providing multiple unit dosage but there are 
many limitations in what concerns the microencapsulation 
technology and growth factor stability. Other strategies involve 
the use of genetically modified cells which arises safety issues 
due to viral vectors or the application of mechanical devices 
that allow the delivery of multiple proteins simultaneously. 
However, non-biodegradable systems imply further surgical 
removal.[11,34,35]
There are also some technical requirements that should be 
taken into account when preparing a NGC. It should be able 
to be sutured onto the nerve stumps and it should be able to 
bear surgical handling. NGC should exhibit a long-term storage 
and has to be sterilizable, as all medical devices that are created 
for implantation purposes.[36] Also, to facilitate its implantation, 
transparent NGC are preferred.
4. Peripheral Nerve Regeneration: Strategies
In the search for an efficient method to bridge nerve gaps with 
success, a vast portfolio of materials and different approaches 
has been proposed. In this section, the most common ones, 
as well as their advantages and disadvantages are going to be 
discussed.
4.1. Nerve Autograft
For the last 50 years, nerve autograft has been considered the 
gold standard for bridging nerve gaps.[21] Autografting was 
reported for the first time between 1870 and 1900, and Mil-
lesi was the first researcher demonstrating the benefits of this 
technique using animal studies.[29] The technique consists in 
harvesting a nerve from another site of the body, which is then 
used to connect the two nerve stumps and align the fibers 
to allow functional recovery of the injured nerve. The most 
common nerve used in this approach is the sural nerve, taken 
from the back outer ankle.[16,29] The factors that affect the choice 
of the most suitable nerve to harvest is related to the location of 
the nerve to be repaired, size and diameter of the nerve gap and 
associated donor-site morbidity.[37]
The use of nerve autografts bring some advantages because 
they act like immunogenically inert scaffolds that have the 
ability to provide the appropriate neurotrophic factors and 
Schwann cells.[29,37,38] However, this technique also has many 
disadvantages, such as: donor site morbidity due to har-
vesting; donor site mismatch; limited supply; requirement of 
a second surgery; possibility of painful neuroma formation 
and scarring; and loss of function, especially in injuries of the 
motor nerves.[21,23,29,38,39] Additionally, the use of nerve auto-
grafts is limited to nerve gaps with lengths of approximately 
5 cm.
4.2. Nerve Allograft
The use of nerve allografts in the regeneration of nerves was 
reported for the first time in 1885, by Albert Einige. This tech-
nique consists of harvesting the missing nerve material from 
humans cadavers, followed by the implantation and suture to 
the injured nerve.[40] Nowadays, allografts are mostly used for 
segmental nerve injuries.[16] They can be used fresh, or pre-
treated by techniques such as freezing, freeze-drying, freeze-
thawing, pre-degeneration and chemical treatments with or 
without immunosuppressants.[38]
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Table 2. Most common growth factors used in nerve guide 
conduits.[19,31,33]
Growth Factor Function
Nerve growth factor 
(NGF)
Involved in the survival of the sensory nerve cell  
bodies and outgrowth of their neurites.
Glial Growth factor 
(GGF)
Induces schwann cell motility and proliferation. Helps 
improving the survival of motor/sensory neurons.
Fibroblast growth 
factor (FGF)
Stimulates mitogenesis which increases  
cell growth and regeneration.
Glial cell-derived 
neurotrophic factor 
(GDNF)
Improve motor/sensory neuron survival, neurite  
outgrowth and schwann cell migration.
Neurotrophin – 3 Restoration of sensory/motor conduction velocity.
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advantages of using these materials is related to the fact that 
there is an abundant supply of donor nerves.[37]
However, many disadvantages are also associated to this 
technique, being the most important the occurrence of an 
undesirable immune response, and the need for systemic 
immunosuppression to prevent rejection and potential immu-
nogenicity.[41] At the same time, the patient is really prone to 
infections, disease transmission risk and in the most severe 
cases, even tumor formation.[16] Immunosuppression can be 
avoided when nerve allografts are decellularised.[42] A commer-
cial product with these characteristics has already been com-
mercialized under the tradename of AxoGen. This device acts 
as a scaffold whose structure is provided by the extracellular 
matrix.[16]
FDA approved a commercial product called Avance, made 
of cadaveric material, which does not need immunosuppres-
sion.[36] This material has all the advantages associated with 
the nerve allografts, and allows the choice of the type of nerve 
needed. However, over time, immunosuppression may be 
required.[36]
Due to the problems listed above concerning nerve auto-
grafts and allografts, new alternatives using different materials 
need to be investigated. Natural materials, biopolymers and 
synthetic polymers have been used to produce NGC and tested 
in order to enhance nerve regeneration. The following sections 
describe the materials that have been used, their structure, for-
mulations and clinical trials results.
4.3. Natural Materials for Nerve Conduits
4.3.1. Blood Vessels
Blood vessels, such as arteries and veins, have been used to 
bridge nerve gaps since the first years of the 19th century. The 
use of arteries was first reported in 1891 with good results, 
but the lack of suitable donor vessels made this technique fall 
into unpopularity and its clinical implementation has never 
occurred.[43]
Veins began being used in 1909, and since then many experi-
ments were carried out. One of the most interesting conclu-
sions was that the application of veins as NGC was more suc-
cessful when nerve slices were used to seed its lumen.[43] This 
interposition was considered a practical and reliable procedure 
for nerve gaps between 2 and 4.5 cm.[43]
One of the main advantages in using veins is that they 
are extremely abundant and induce less donor-site mor-
bidity.[38] However, the possibility of collapsing due to their 
thin walls, turn veins a non-recommended tissue for gap 
bridging.[44]
4.3.2. Muscle
Skeletal muscle in nerve repair applications was first reported 
in 1940.[45] Studies demonstrated that fresh and denatured con-
duits made from muscle could lead to regeneration of nervous 
tissue. As to the advantages of its use, it has extracellular matrix 
components and longitudinally oriented basal lamina. These 
factors are extremely useful for enhancing nerve regeneration 
as this microenvironment helps to promote cell adhesion.[38] 
Also, it can be noted that there are numerous donor sites from 
which muscle tissue can be harvested.[43] However, this fact rep-
resents a disadvantage because a harvesting procedure has to 
be performed. Moreover, using muscle has its risks, as some 
nerve fibers may grow out of the muscle tissue while the regen-
eration process is occurring.[43]
4.3.3. Tendon
Tendon from rat tail has already been used for nerve regen-
eration. In the most known experiment, a 10 mm nerve gap 
was bridged.[46] As the rat tail tendon has extracellular matrix 
components and also a longitudinal arrangement of collagen, 
it constitutes a good path for cells to adhere to during nerve 
regeneration.[43] In terms of morphometric and functional eval-
uation, the results obtained by autografting are quite similar to 
muscle graft. Unlimited source of graft material, as well as lim-
ited loss of function, are the main advantages of these tissues 
for nerve bridging.[38]
Reports concerning the use of natural materials in nerve 
regeneration are summarized in Table 3.
4.4. Natural Polymers
Following nerve allografts, natural polymers were seen as reli-
able alternative materials to construct nerve autografts.[30] The 
most common naturally-derived polymers used in nerve regen-
eration are collagen, chitosan and alginate.
4.4.1. Collagen
Collagen is a structural protein of connective tissues in humans 
and animals and the major component of extracellular matrix 
(Figure 2).
Due to this fact, it has been used in implants as wound 
dressings and artificial skin.[28] It is a natural biodegradable 
material with high biocompatibility, low antigenicity, which is 
known to promote neurite outgrowth, nerve regeneration and 
helps to maintain biological functions of the cells.[28,30,59,60]
This material has been used as NGC since 1990s, adopting 
different forms. FDA already approved some nerve guide 
devices using Type I Collagen. Table 4 summarizes their 
features.
These include fibers inserted inside the conduit’s lumen to 
function as fillers and hydrogel formulations to deliver cells, 
drugs or growth factors.[28]
Some studies have also shown that collagen filaments incor-
porated in NGC made with biodegradable materials, help to 
guide the new nerve fibers as they improve permeability and 
surface area exposed to the surrounding tissue.[59]
As collagen is a natural polymer, it presents poor mechan-
ical strength, high water uptake and fast degradation, which 
Adv. Healthcare Mater. 2016, 5, 2732–2744
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are undesirable characteristics in nerve regeneration. Indeed, 
the structural integrity is compromised and the swelling can 
compress the new nerve tissue as it is growing.[30] To over-
come such disadvantages, some techniques, like solution 
casting and freeze-drying, are being performed to achieve the 
required mechanical strength and porosity.[30] The mechanical 
strength can also be improved by crosslinking collagen between 
amine groups, which provides structural stability to the NGC.[2] 
Among the techniques used for preparation of collagen nerve 
conduits, the most reported ones include injection molding 
and dip-coating, extrusion, electrospinning, freeze drying fol-
lowed by lyophilization and crosslinking due to microwave 
radiation.[2,27] Table 5 presents some of the works where col-
lagen was used as NC.
4.4.2. Chitosan
Chitosan (Figure 3) is a cationic biopolymer obtained from the 
alkaline deacetylation of chitin, which is the most abundant 
natural polymer after cellulose.[69,70]
Over the years, chitosan has been widely used in several 
biomedical applications,[70–75] mainly because of its promising 
intrinsic properties. Among them, it is possible to mention: 
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Table 3. Summary of the natural materials used in NGC, and main results obtained.
Year Material Nerve Gap (mm) Animal Results Ref
1982 Vein Sciatic 10 Rat Conduction restored after 4 months of surgery [47]
1984 Vein Sciatic 25 Rat Satisfactory results with minimal scar tissue formation [48]
1986 Artery Peroneal 5 Rat Growth of a minority of axons [49]
1986 Muscle Sciatic 40 Rat and Rabbit Satisfatory limb function recovery [50]
1986 Vein Femoral 14 and 2 Rabbit Smaller gap had better remyelination comparing with the longer one [51]
1988 Vein Sciatic 5 Rat Nerve vein graft conduction velocity similar to autogenous nerve graft [52]
1989 Vein Peroneal 10 Rat Vein graft shower similar pattern of nerve regeneration as nerve graft [53]
1992 Aortic Tibial 10 Rat Preferential growth toward the distal nerve was observed [54]
1992 Muscle Peroneal 50 Rat Muscle graft did not lead to reliable recovery [55]
1993 Vein Sciatic 10 Rat Compared with polyethylene nerve conduit, vein graft showed accelerated  
rate of nerve regeneration and significantly earlier myelination.
[56]
1994 Vein Sciatic 10 Rat Small regenerated axons [57]
2007 Muscle+Vein Median 10 Dog Fresh and predegenerated skeletal muscle present similar results after  
1 month regarding to integrity
[58]
Figure 2. Chemical structure of collagen type I. (A) secondary left handed helix and tertiary right handed triple-helix structure, (B) primary amino acid 
sequence). Reproduced with permission.[61] Copyright 2011, Springer.
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biocompatibility,[39,75,76] biodegradability,[69,75] low toxicity and 
non-immunogenicity,[69,75,76] low cost and large availability.[75,76]
Very recently, chitosan started to be used in the fabrication of 
NGC for peripheral nerve regeneration, with some success.[74] 
The good results obtained might be due to the favorable inter-
action of chitosan with biological environments, namely the 
promotion of cell attachment, adhesion, differentiation, and 
survival, ability to create a good pathway for neurite outgrowth 
and ability to inhibit the scarred tissue formation.[39,75,77]
Unfortunately, some structural properties of this biopolymer 
are not suitable for the construction of NGC, its mechan-
ical strength being the most critical issue. As it presents low 
mechanical strength under physiological conditions, the capa-
bility to maintain a certain structure, needed to guide the new 
fibers, is seriously compromised.[71,73,75] Usually, chitosan is 
subjected to a crosslinking reaction with, for instance, gen-
ipin,[78] to compensate the lack of mechanical strength. This 
formulation was already tested in many biomedical applications 
such as drug carriers and in the encapsulation of biological 
products and living cells.[78] The addition of chitin powder to 
chitosan solution has also been tested to increase mechanical 
strength.[79]
Along with mechanical strength, porosity is also a property 
which has to be optimized in order to achieve the adequate 
value.[78] Porosity is related to the fabrication procedure of the 
material to be implanted. The most common techniques used 
are cast molding, with molds made of stainless steel, and 
knitting techniques combined with lyophilization have been 
used.[39,75,79]
Table 6 presents some studies regarding the use of chitosan 
in nerve regeneration, as well as their main results, performed 
since the middle 2000s.
4.4.3. Poly(3-hydroxy butyrate) (PHB) and Poly(3-hydroxybutyrate-
co-hydroxyvalerate) (PHBV)
Poly-3-hydroxbutyrate (PHB) is a bio-absorbable polymeric 
material that is synthesized by microorganisms that use 
determined substrates as carbon sources, under conditions of 
limiting nutrients.[83] It can be produced from fermentation fol-
lowed by solvent extraction from bacterial cultures and carbon 
substrates.[84] Its copolymer with 3-hydroxyvalerate, poly(3-
hydroxybutyrate-co-hydroxyvalerate) (PHBV), is more flexible 
and easier to process when compared with PHB. PHB is usu-
ally molded into a sheet made with aligned fibers, and at the 
end of the 1990s the first attempts in using this material for 
peripheral nerve regeneration were reported showing effect on 
helping regeneration of axons.[85] PHB is non-antigenic and 
presents good tensile strength, but its degradation lasts at least 
24 to 30 months till all polymer is resorbed.[84] Some years later, 
a comparative study between the performance of PHB with 
epineural suturing was carried out in the median and/or ulnar 
nerve at the wrist/forearm level. The results suggested better 
recovery with PHB than with epineural suturing.[83] The effect of 
blending PHB and PHBV has also been studied. The resulting 
material is easier to handle as its melting point decreases. After 
the blending, the scaffold was obtained by electrospinning. Sat-
isfactory results were obtained in this study as good Schwann 
cells proliferation was observed, which increased with the addi-
tion of collagen to the scaffold.[86] More recently, Biazar et al. 
have been performing studies using PHBV as the unique mate-
rial for the preparation of nerve guide tubes, achieving inter-
esting results in what concerns mechanical properties. Also, 
as the nerve guide was micro patterned, improvement in adhe-
sion of Schwann cells was observed.[41] Later, the same author, 
crosslinked PHBV with gelatin, and the resulting material 
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Table 4. Type I Collagen devices approved by FDA for peripheral nerve regeneration.[36]
Type of device Product Name Degradation Diameter Length Company
Nerve guide NeuraGen 36–48 months 1.5–7 mm 2–3 cm Integra Life Sciences Corp.
Nerve guide Neuroflex 4–8 months 2–6 mm 2.5 cm Collagen Matrix Inc.
Nerve guide NeuroMatrix 4–8 months 2–6 mm 2.5 cm Collagen Matrix Inc.
Nerve cuff/protectant wrap NeuraWrap 36–48 months 3–10 mm 2–4 cm Integra Life Sciences Corp.
Nerve cuff/protectant wrap NeuroMend 4–8 months 4–12 mm 2.5–5 cm Collagen Matrix Inc.
Table 5. NGC made with collagen submitted to in vivo tests.
Year Material Nerve Gap (mm) Animal Results Ref
1983 Collagen Radial 8 Cat Reinnervation of sensory structures [62]
1990 Collagen-PGA Peroneal 0.5 Rat Axonal regeneration equal to sutured autografts [63]
1991 Collagen Sciatic 4 Rat Nerve regeneration similar to nerve autograft [64]
2009 Collagen Peroneal 10 Rat Regeneration of motor axons with no noticeable foreign body reaction [59]
2010 Collagen Peroneal 30 Dog Functional recovery of the regenerated nerve [65]
2013 Collagen Median 10–20 Human 8 in 9 patients achieved functional recovery [66]
2013 Collagen Digital ≤26 Human Useful to span digital nerve defects up to 2.6 cm [67]
2014 Collagen-Collagen fibers Sciatic – Rat Nerve regeneration similar to nerve autograft [60]
2014 Collagen Sciatic 10 Rat Study of the influence of the conduit diameter for motor recovery [68]
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showed improved cellular adhesion in comparison with PHBV 
alone. The tube was used to bridge a gap with 30 mm in the 
sciatic nerve of a rat. After four months, restoration of the nerve 
and myelated nerve fibers were observed.[41] More recently a 
study has been reported where PHBV was crosslinked with 
laminin, proving that cell adhesion on its surface was improved 
compared with the neat PHBV.[87] All these results show that 
most specifically PHBV is a promising material for peripheral 
nerve regeneration due to good mechanical properties, cellular 
interaction, and also the possibility to control the degradation 
rate of its constructs.
4.4.4. Alginate
Alginate is a linear polysaccharide copolymer of (1-4)-linked 
β-D-mannuronic acid (M) and α-L-guluronic acid (G), extracted 
from brown seaweed.[4] It is biocompatible, biodegradable, ster-
ilizable without degradation, and, very importantly, its physical 
and rheological properties can be easily modified by varying the 
monomers (G and M) ratio and molecular weight of the polymer 
chain.[4,88] Since the past decade, the interest in alginate for bio-
medical applications has increased significantly due to its good 
cell compatibility.[89] Alginate based hydrogels have been used 
as covers for diabetes treatment and hemophilia, detoxification, 
transplanted pancreas or liver cells, and as bridging materials 
for both spinal cord and nerve repair.[4,90] In what concerns the 
nerve regeneration, the compatibility of this biopolymer with 
Schwann cells, neurotrophic factors and stem cells is a very 
interesting and the most decisive characteristic.[4,90,91]
In peripheral nerve regeneration, alginate is usually used 
as a gel which is inserted in the conduit lumen to guide the 
new nerve fibers. However, it is reported in literature that the 
regeneration of nerve tissue requires that some quantity of gel 
has to degrade, in order to open space in the lumen.[91] This gel 
usually results from the crosslinking of alginate with calcium 
ions.[91] The gel degradation starts with the diffusion on the cal-
cium ions from alginate, allowing the slow loss of crosslinking 
of the alginate gel. The resulting products are immunologically 
inert and are not digested by mammalian cells.[90]
Alginate gels have been tested both in vitro and in vivo for 
peripheral nerve regeneration purposes, but contradictory 
results were obtained. In vitro tests showed a negative influ-
ence of alginate on cell proliferation. Unexpectedly, in vivo 
tests showed the opposite. A sciatic nerve gap with 7 mm 
in rats and a sciatic nerve gap with 50 mm in cats were suc-
cessfully bridged with alginate foams, leading to promising 
results.[28] Because of this paradox, and due to ethical issues, 
alginates are not widely used materials for peripheral nerve 
regeneration. More recently, the attempt to crosslink alginate 
with chitosan has been reported, and interesting results were 
achieved.[89]
Other materials such as hyaluronic acid, natural silk, silk 
fibroin and keratin have also been tested, but not as intensively 
as the former ones. These materials lack some important prop-
erties, namely mechanical stability. Consequently, the only way 
to use them is by chemical modifications via crosslinking or by 
incorporation in other natural or synthetic biomaterials.[28]
4.5. Synthetic Polymers
During the last years, enormous efforts have been made to 
create NGC based on synthetic polymers. Typically, these mate-
rials can be classified as non-degradable and degradable.
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Figure 3. Chitosan structure
Table 6. Chitosan membranes and NGC tested for nerve regeneration in vivo.
Year Material Nerve Gap (mm) Animal Resultados Ref
2004 Chitosan-chitin powder Sciatic 8 Rat Compatible with the surround tissue in vivo [79]
2005 Chitosan-neurosteroids Facial 10 Rabbit Regeneration of the nerve fibers. Faster regeneration when  
using the neurosteroids in vivo
[80]
2005 Chitosan-Filaments 
of PGA
Sciatic 30 Dog Restoration of nerve continuity and functional recovery [39]
2009 Chitosan-GDNF Sciatic 10 Rat Axon area and myelination higher than chitosan tube (control) [69]
2010 Cross-linked carboxy-
methyl chitosan
Sciatic 10 Rat Myelin sheath similar to nerve autografts and higher fiber  
density compared to chitosan tube
[70]
2013 Chitosan with varying 
degrees of acetylation
Sciatic 10 Rat Poor mechanical properties and low stability [73]
2013 Collagen-Chitosan with 
RGD
Sciatic 15 Rat Faster regeneration with RGD compared with  
collagen-chitosan tubes
[81]
2015 Chitosan Phrenic 15 Dog Functional recovery was not totally achieved [82]
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While trying natural polymers, researchers also focused their 
interest on non-biodegradable polymeric materials to be used in 
nerve regeneration due to their superior mechanical properties. 
Good results were achieved for small gaps, but in many cases 
the conduits had to be removed due to immunologic response. 
The next topic presents the most used non-degradable poly-
meric materials for nerve regeneration purposes and also the 
new trends in using these materials.
Silicone: Since 1960s, silicone has been studied as material 
for NGC in peripheral nerve regeneration. It was one of the 
first synthetic materials to be used in these applications due to 
its elastic properties and inertness.[28] It is non-biodegradable 
and non- permeable to large molecules.
The first researcher to present a successful case of recovery 
from an injury using silicone was Merle.[92] Some years 
later, Chen, doped silicone tubes with laminin, collagen and 
fibronectin gels, concluding that better results than the non-
doped silicone tube can be achieved.[93] Lundborg, in turn, 
concluded that silicone tubes gave better regeneration results 
in gaps smaller than 5 mm.[94–97] This was confirmed after 
another study where a 8 mm gap in the peroneal nerve of the 
rat was bridged with a silicone tube showing the presence of 
new axons, although some of them not myelinated.[98] How-
ever, many works in rats also reported the formation of scarred 
tissue, compression of the new axons or even no regeneration 
at all.[99–101]
Moreover, researchers also refer that in some patients, sili-
cone tubes had to be removed because of loss of nerve func-
tion due to irritation at the implantation site. As this material 
is non-biodegradable, a chronic inflammation associated to 
excessive scarred tissue formation can occur during time, in 
some cases, after one week.[24] Contradictory results have been 
more recently reported in histomorphometrical and immuno-
histochemical assessments, which supported that no excess of 
scarred tissue was formed and axons can regenerate within a 
silicone tube.[102] Ikeguchi et al. implanted negative-charged 
carbon ions in the inner surface of a silicone tube, claiming 
that axonal regeneration was improved.[103] Unfortunately, none 
of these recent works gives further information concerning the 
consequences that this type of conduits could evoke a long time 
after implantation.
Expanded poly(tetrafluorethylene) (ePTFE): ePTFE was dis-
covered in the 1970s and it’s chemically identical to PTFE but, 
after processing, it presents billions of small pores. This porous 
structure can be obtained without the use of soluble fillers, 
foaming agents or other chemical additives.[104]
It is used to make lightweight, waterproof and breathable 
fabrics, micro-porous membranes, microwave carriers, indus-
trial sealants and high-tensile fabrics and cords and medical 
tubes and implants.[104]
For peripheral nerve regeneration, a product made from 
ePTFE is commercialized under the tradename of Gore-Tex. 
The main conclusions taken from in vivo trials in humans were 
that small gaps in the lower arm (15–40 mm) were successfully 
bridged, but longer defects (till 60 mm) could not recover and 
useful reinnervation was only verified in 13.3% from a popula-
tion of 43 patients.[29]
In another trial, Gore-Tex was used in seven patients with 
nerve defects (< 3 mm) in the inferior alveolar nerve, and only 
two of them revealed some return of sensation.[104] Also, this 
product causes an excess of scarred tissue formation, compres-
sion of the new fibers and severe immunologic responses from 
the host body. Nowadays, and for these reasons, these materials 
are lacking the interest from the medical field.
Polypyrrole (Ppy): Ppy is a conductive polymer which is com-
monly used in advanced materials such as sensors, solar cells, 
water treatment materials, among others.[105] It has been object 
of interest for peripheral nerve regeneration in recent years due 
to the positive responses induced in cells by electric stimula-
tion.[106] Among the many advantages of using this material 
there is the fact that it can support cell adhesion and has a good 
biocompatibility and no evidence of toxicity.[107] The first time 
that neurite outgrowth from PC12 cells in contact with a film 
of Ppy was reported was in 1997 proving that conductive poly-
mers could be useful for nerve regeneration applications.[108] 
After these findings, researchers have tried to incorporate new 
features to Ppy based NGC, such as the incorporation of adhe-
sive cells. Also, changing the topography of these materials has 
proved to help in the regeneration of new axons due to guid-
ance providence.[109] Unfortunately, the use of Ppy brings some 
disadvantages, namely those related with its slow degradation 
rate and poor solubility.[110] For that reason, Ppy has been incor-
porated in composite materials as a way to overcome its draw-
backs. Using emulsion polymerization, Xu et al. prepared Ppy/
PDLLA conductive composites and it was found that the mate-
rials were able to support neurite regrowth in a similar way to 
that of autologous grafting.[110] More recently, nerve guide tubes 
based on PVA/Ppy were also studied. The tubes were prepared 
using a casting technique and molded in a silicone tube. A 
satisfactory number of regenerated nerve fibers was achieved 
although better results were obtained by a conduit based on 
PVA loaded with multi-wall carbon nanotubes (MWCNT) 
seeded with Mesenchymal stem cells (MSCs).[111] In conclu-
sion, conductive polymers have demonstrated to be promising 
materials for peripheral nerve regeneration, when blended with 
other polymers with more desirable solubility, mechanical and 
degradation properties.
4.5.2. Biodegradable Polymers
Due to the problems caused by non-biodegradable polymers, 
their biodegradable counterparts have started to be more pop-
ular for peripheral nerve regeneration. These materials have the 
ability to fully degrade in vivo, which leads to a new approach 
for this application: by the end of the regeneration, the con-
duit should be gone completely and with that avoid immune 
response from the body. Many biodegradable materials were 
tested, but in this section only poly(glycolic acid) (PGA), 
poly(lactic acid-co-glycolic acid) (PLGA), poly(ε-caprolactone) 
(PCL), and poly(DL-lactic acid –co-ε-caprolactone) (P(DLLA-
co-CL)) will be presented, as they are those with more clinical 
trials and with FDA approved products.
PGA: PGA is an aliphatic polyester known in the biomedical 
field as a suture material for wound closure. It has been used 
for a long time in this application because it can be absorbed by 
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the human body within 90 days after implantation, through an 
hydrolysis mechanism.[112] Due to its good biological properties, 
the interest in producing NGC from this material has increased 
substantially.
PGA was first used as a NGC in 1990, by Mackinnon and 
Dellon, and the results were similar to those obtained from 
nerve autografting.[113]
Although several works report good results, others refer that 
PGA alone has a too fast degradation rate, which can be unde-
sirable for larger nerve gaps. Another problem concerns the 
technique used to fabricate the conduit. When extrusion was 
used, the surface of PGA conduits presented poor quality.[43] 
Moreover, while it degrades, the products that are released have 
an acidic nature, leading to the decrease of the pH at the site of 
implantation that can trigger the immune response.
A new approach was then adopted and involved the use 
of PGA, not as the core material of the nerve conduit, but as 
filler.[114] Good results came from these works, which lead 
researchers to conclude that PGA is a good material for nerve 
regeneration, especially when combined with other materials, 
of which chitosan and collagen are examples.[115–118]
In 1999, the first commercial product made from PGA was 
approved by the FDA under the tradename of Neurotube, 
which is indicated for bridging gaps between 2–4 cm. It pre-
sents a diameter of 2.3–8 mm and degrades within approxi-
mately 3 months.[36]
PLGA: PLGA is an aliphatic copolyester made from glycolic 
and lactic acid that has FDA approval and has been used as a 
suture material throughout the years (Polyglactin 10).[119] Dif-
ferent ratios of the two monomers allow the tailoring of the 
polymer properties (e.g., thermomechanical, wettability, 
swelling and degradation), which is an advantage of PLGA over 
PGA.[119] The ability to manipulate the degradation ratio, which 
allows tailoring the material for different types and sizes of 
nerve gaps, turns PLGA a very attractive material for peripheral 
nerve regeneration.
PLGA is biodegradable, and releases acidic products during 
degradation, which presents the deleterious effect described 
above.
In NGC production, PLGA has been tested as the core mate-
rial of the conduit and also in combination with others (e.g., 
collagen). When used alone, in order to turn it permeable and 
with an adequate porosity, some approaches have been tested, 
namely the addition of a porogen agent[120] and preparation of 
hollow fiber membranes using a phase-inversion process.[121] In 
both works, interesting mechanical properties and degradation 
profiles were achieved. In a more recent study, a PLGA based 
catheter was prepared.[122] This catheter comprises an outer tube 
which has a scaffold inside. This scaffold has many tube shaped 
structures in order to correctly guide the new nerve fibers. The 
outside tube provides the mechanical support required for 
nerve regeneration. As a result, fibroblast growth was facilitated 
across the inner scaffold and also the outer structure showed 
good capacity to overcome compression.[122] PLGA had also 
been electrospun and then coated with a conductive polymer, 
Ppy. An in vitro assessment with PC12 rat cells showed the 
formation of longer neuritis compared with the control.[123] In 
another approach, PLGA conduits were coated with nanosilver 
to benefit from silver’s antimicrobial effect which resulted in an 
increase of infection resistance of the conduit.[124] A combina-
tion of electrospun PCL with nanospheric PLGA was also tested 
with PC12 rat cells, revealing long and guided neuritis due to 
the alignment provided by the scaffold.[125]
Neurotrophic factors, as well as Schwann cells, have also 
been incorporated in PLGA matrices leading to good results, 
but only in small gaps. Nevertheless, PLGA does not represent 
a good alternative for peripheral nerve regeneration in general, 
as only some specific cases can be treated with this polymer. 
Table 7 shows the main conclusions of the works reported in 
literature that used this polymer in nerve regeneration.
PCL and P(DLLA-co-CL): PCL is a bioresorbable, hydro-
phobic and semi-crystalline polyester.[131] Its tailorable degra-
dation and mechanical properties, along with its good compat-
ibility, have made this polymer very attractive to the biomedical 
field since the 1970s. During this time, it was used in various 
drug delivery systems, but as its degradation rate was slow, 
other resorbable polymers as PGA and poly(D,L-lactide) (PDLA) 
were preferred for this kind of applications.[132] However, since 
the 2000s, as tissue engineering arose, PCLs has been exten-
sively tested both in vitro and in vivo revealing good results in 
terms of biocompatibility. As a result, FDA approved its use in 
tissue engineering applications.[133]
For peripheral nerve regeneration, this polymer, in simi-
larity with other bioabsorbable polymers, has been tested in 
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Table 7. PLGA based NGCs tested in vivo.
Year Material Nerve Gap (mm) Animal Results Ref
2004 PLGA(85:15)+Schwann cells sciatic 10 Rat Ultrasonic stimulation has a positive effect on seeded Schwann  
cells within PLGA conduit
[126]
2006 PLGA(75:25)+collagen peroneal 15 rabbit PLGA-coated collagen tube showed better regeneration  
comparing to vein grafts
[119]
2006 PLGA(85:15) sciatic 10 Rat Asymmetric structure enhance the removal of drained waste [127]
2007 PLGA (90:10; 50:50)+Schwann cells sciatic 10 rat Directional permeability has a positive effect in nerve  
regeneration through PLGA conduits
[5]
2007 PLGA (90:10) sciatic 10 rat Axon regeneration similar to Neurolac [128]
2008 PLGA/Pluronic F127 sciatic 10 rat Regeneration achieved due to good mechanical properties,  
permeability and prevention of scar tissue invasion.
[129]
2010 PLGA/Chitosan+CNTF tibial 25 dog Favorable conduit for Schwann cell migration and axonal regeneration [130]
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conduits alone, mixed with other polymers and seeded with 
both cells and nerve growth factors. Improvement of the motor 
function of the sciatic nerve was achieved with a PCL conduit 
seeded with MSCs.[134] In a study of the topography of the 
surface and mechanical properties, NGC based on PCL–PVA 
were prepared by solvent casting.[23] The presence of a grooved 
structure helped reducing the excessive mechanical proper-
ties of the material, approximating it to the ones of the healthy 
nerve. Another study evaluated the effect of encapsulated neu-
rotrophic factor derived from glial cell (GDNF) embedded in a 
nerve conduit made with PCL.[135] The bioactivity of GDNF was 
confirmed and also the sterilization technique proved to be suit-
able for this material, as it did not alter its structure or porosity 
percentage. More recently, works including the use of peptides 
as RGD with PCL based surfaces have also been reported, and 
promising results were obtained.[136]
Table 8 shows some in vivo studies performed with PCL 
based NGCs.
P(DLLA-co-CL) is a polyester made from D,L-lactic acid and 
ε-caprolactone that has attracted the interest of the researchers 
for peripheral nerve regeneration. It should be mentioned 
that problems derived from its degradation in vivo lead to less 
damage of the surrounding tissue, as their degradation prod-
ucts are less acidic when compared with PGA or PLGA.[128]
On the other hand, compared with the other biodegradable 
materials, P(DLLA-co-CL) is more hydrophobic, which can lead 
to higher degradation times, extending the life time of the con-
duit in the body. Moreover, in some cases, even after the nerve 
is regenerated and functional activity is restored, there still 
small fragments of the nerve conduits standing by the new 
nerve.[36] FDA gave approval to a commercial product made 
from this copolyester known as Neurolac. This conduit has a 
diameter of 1.5–10 mm and length of 3 cm. In terms of degra-
dation, it only degrades completely after 16 months.[36]
5. Outlook and Conclusions
Peripheral nerve injury is a problem affecting millions of 
people all around the world, with consequences that can lead 
to irreversible disability. The preparation of a device able to 
improve the recovery ratios after peripheral nerve injury still 
remains a clinical challenge. After mid-1980s, some devices 
received FDA approval, which include those made from natural 
and synthetic polymers. Unfortunately, none of these devices 
has all the desirable characteristics for achieving better results, 
since they present limited repair for gaps longer than 30 mm[59] 
and are also somewhat expensive. It is believed that the trend 
of peripheral nerve regeneration is to create devices, which can 
be adapted to different gap lengths. Also, the inclusion of exog-
enous cells to enhance the recovery of the nerve has received 
considerable interest in the last years showing promising 
results. Another approach that has been proposed is the use of 
polymeric materials with conductive properties, namely Ppy. 
Although some preliminary results have shown that conductive 
properties are effective in promoting nerve regeneration, in the 
authors opinion, this property should be attained by modifying 
biodegradable materials, since Ppy is non-biodegradable. The 
use of non-biodegradable materials in this application, as men-
tioned in this manuscript, can be seen as a disadvantage as the 
material may constrict the new nerve fibers and a second sur-
gical intervention may be needed for its removal.
To sum up, in the authors’ opinion, polymeric materials 
seem to be a reliable solution to prepare such nerve conduits, 
since their properties can be easily modified and also allow the 
easy incorporation of nerve growth factors and accessory cells, 
which play an important role in successful regeneration of the 
injured nerve.
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